170 related articles for article (PubMed ID: 19549212)
1. Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma.
Becker L; Huang Q; Mashimo H
Dis Esophagus; 2010 Feb; 23(2):168-74. PubMed ID: 19549212
[TBL] [Abstract][Full Text] [Related]
2. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus?
von Rahden BH; Kircher S; Lazariotou M; Reiber C; Stuermer L; Otto C; Germer CT; Grimm M
J Exp Clin Cancer Res; 2011 Feb; 30(1):23. PubMed ID: 21345220
[TBL] [Abstract][Full Text] [Related]
3. LGR5 in Barrett's Esophagus and its Utility in Predicting Patients at Increased Risk of Advanced Neoplasia.
Neyaz A; Odze RD; Rickelt S; Nieman LT; Bledsoe JR; Mahadevan KK; Arora K; Jeck WR; Taylor MS; Gala M; Patil DT; Yilmaz OH; Rivera MN; Ting DT; Deshpande V
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00272. PubMed ID: 33464729
[TBL] [Abstract][Full Text] [Related]
4. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
5. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.
Vega KJ; May R; Sureban SM; Lightfoot SA; Qu D; Reed A; Weygant N; Ramanujam R; Souza R; Madhoun M; Whorton J; Anant S; Meltzer SJ; Houchen CW
J Gastroenterol Hepatol; 2012 Apr; 27(4):773-80. PubMed ID: 21916995
[TBL] [Abstract][Full Text] [Related]
6. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
[TBL] [Abstract][Full Text] [Related]
7. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
8. High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5.
Abu-Farsakh S; Wu T; Lalonde A; Sun J; Zhou Z
BMC Gastroenterol; 2017 Feb; 17(1):33. PubMed ID: 28212604
[TBL] [Abstract][Full Text] [Related]
9. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus.
Larghi A; Lightdale CJ; Memeo L; Bhagat G; Okpara N; Rotterdam H
Gastrointest Endosc; 2005 Jul; 62(1):16-23. PubMed ID: 15990814
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
11. High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.
Fisher OM; Levert-Mignon AJ; Lord SJ; Botelho NK; Freeman AK; Thomas ML; Falkenback D; Wettstein A; Whiteman DC; Bobryshev YV; Lord RV
Ann Surg Oncol; 2015 Jul; 22(7):2431-8. PubMed ID: 25348778
[TBL] [Abstract][Full Text] [Related]
12. Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma.
Schellnegger R; Quante A; Rospleszcz S; Schernhammer M; Höhl B; Tobiasch M; Pastula A; Brandtner A; Abrams JA; Strauch K; Schmid RM; Vieth M; Wang TC; Quante M
Cancer Prev Res (Phila); 2017 Jan; 10(1):55-66. PubMed ID: 27807078
[TBL] [Abstract][Full Text] [Related]
13. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
[TBL] [Abstract][Full Text] [Related]
14. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of young patients with early Barrett's neoplasia.
Iwaya Y; Shimamura Y; Goda K; Rodríguez de Santiago E; Coneys JG; Mosko JD; Kandel G; Kortan P; May G; Marcon N; Teshima C
World J Gastroenterol; 2019 Jun; 25(24):3069-3078. PubMed ID: 31293342
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic correlation between the expression of the DNA repair enzyme N-methylpurine DNA glycosylase and esophageal adenocarcinoma onset: a retrospective pilot study.
Zaïr ZM; Johnson GE; Griffiths AP; Jenkins GJ
Dis Esophagus; 2013 Aug; 26(6):644-50. PubMed ID: 23137018
[TBL] [Abstract][Full Text] [Related]
18. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
20. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
